Validation of the NSABP/NRG Oncology 8-gene trastuzumab-benefit signature in Alliance/NCCTG N9831
Menée à partir des profils d'expression génique de 892 patientes atteintes d'un cancer du sein HER2+, cette étude met en évidence une signature, basée sur l'expression de 8 gènes, pour identifier les patientes pouvant bénéficier du trastuzumab dans le cadre d'un traitement par chimiothérapie
Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2+ breast cancer patients. NSABP investigators utilized gene expression profiles of N9831 patients (N = 892) to blindly assign patients to large-, moderate-, or no-trastuzumab benefit groups and then assessed the degree of trastuzumab benefit using Cox models adjusted for age, nodes, ER/PR status, tumor size, and grade. Hazard ratios and two-sided p values for recurrence-free survival of the predicted large- (n = 387), moderate- (n = 401), and no-benefit (n = 104) groups, based on the 8-gene signature were 0.47 (95%CI=0.31 to 0.73, P<.001), 0.60 (95%CI=0.39 to 0.92, P=.02), and 1.54 (95%CI=0.59 to 4.02, P=.38), respectively (interactionP = .02, providing validation of the 8-gene signature in an independent study.
JNCI Cancer Spectrum , article en libre accès, 2019